COMMUNIQUÉS West-GlobeNewswire

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
01/08/2025
Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLOBE NEWSWIRE) -- [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/08/2025
CLEVELAND, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
01/08/2025
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following [...]
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01/08/2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
01/08/2025
Aptose to hold a reconvened shareholder meeting on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on appointment of new auditor SAN DIEGO and TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ [...]
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
01/08/2025
MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access Pathway SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “ [...]
FOXO TECHNOLOGIES INC.’S BIG SOUTH FORK MEDICAL CENTER COMPLETES PERFORMANCE NETWORK AGREEMENT WITH COVENANT HEALTH TO PROVIDE SWING BED SERVICES
01/08/2025
WEST PALM BEACH, FLORIDA, Aug. 01, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“ FOXO ” or the “ Company ”) today announced that its critical access designated rural hospital, Big South Fork [...]
Orchestra BioMed Announces Pricing of $40 Million Public Offering
01/08/2025
NEW HOPE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk- [...]
NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement
01/08/2025
LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]
Legend Senior Living Expands Management Team, Naming Brian Donnelly as Director of Dining Experience
01/08/2025
WICHITA, Kan., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living, a nationally recognized senior living provider which operates over seventy residences in six states, has expanded its management team by adding [...]
Ascentage Pharma to Participate in Evercore China Biotech Summit
01/08/2025
ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”), a global biopharmaceutical company dedicated [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/08/2025
CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
01/08/2025
ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, [...]
OrthoPediatrics Corp. Launches 3P™ Pediatric Plating Platform™ Hip System and Completes First Case
01/08/2025
WARSAW, Ind., Aug. 01, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
01/08/2025
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trial Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial and on track for [...]
Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer
01/08/2025
Seasoned executive with proven track record driving growth and building customer focused teams to lead Milestone’s next phase of commercial execution ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone [...]
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results
01/08/2025
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14 [...]
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
01/08/2025
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC [...]
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
01/08/2025
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the [...]

Pages